The content is available as a PDF (70.5 KB).
References
- 1.Statistics Canada. Leading causes of death. 2011. [Google Scholar]
- 2.Sullivan R, Peppercorn J, Sikora K, Zalcberg J, Meropol NJ, Amir E, et al. Delivering affordable cancer care in high-income countries. Lancet Oncol. 2011;12(10):933–80. doi: 10.1016/S1470-2045(11)70141-3. [DOI] [PubMed] [Google Scholar]
- 3.World Health Organization. Cancer prevention. 2012. [Google Scholar]
- 4.Greenberg D, Earle C, Fang CH, Eldar-Lissai A, Neumann PJ. When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology. J Natl Cancer Inst. 2010;102(2):82–88. doi: 10.1093/jnci/djp472. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Canadian Agency for DrugsTechnologies in Health. Guidelines for the Economic Evaluation of Health Technologies: Canada. 3rd 2006. [Google Scholar]
- 6.Tufts Medical Center. Cost-effectiveness analysis registry. 2012. [Google Scholar]
- 7.Custer B, Agapova M, Martinez RH. The cost-effectiveness of pathogen reduction technology as assessed using a multiple risk reduction model. Transfusion. 2010;50(11):2461–73. doi: 10.1111/j.1537-2995.2010.02704.x. [DOI] [PubMed] [Google Scholar]
- 8.Brisson M, Van de Velde N, De Wals P, Boily MC. The potential costeffectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine. 2007;25(29):5399–408. doi: 10.1016/j.vaccine.2007.04.086. [DOI] [PubMed] [Google Scholar]
- 9.Wong WW, Woo G, Heathcote EJ, Krahn M. Cost-effectiveness of screening immigrants for hepatitis B. Liver Int. 2011;31(8):1179–90. doi: 10.1111/j.1478-3231.2011.02559.x. [DOI] [PubMed] [Google Scholar]
- 10.Anonychuk AM, Bauch CT, Merid MF, Van KG, Demarteau N. A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females. BMC Public Health. 2009;9:401. doi: 10.1186/1471-2458-9-401. [DOI] [PMC free article] [PubMed] [Google Scholar]